Advancing diabetes treatment: the role of mesenchymal stem cells in islet transplantation
Frontiers in Immunology · 28.03.2024 · 15
DOI: 10.3389/fimmu.2024.1389134 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Frontiers in Immunology, online erschienen am 28.03.2024. Verfasst von Lisha Mou und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Endocrinology, Institute of Translational Medicine, The First Affiliated Hospital of Shenzhen University, Shenzhen Second People's Hosp…. Hauptthemen laut MEDLINE: Islets of Langerhans Transplantation, Islets of Langerhans, Diabetes Mellitus, Experimental, Mesenchymal Stem Cell Transplantation. Die Arbeit wurde bisher 18-mal zitiert (Crossref) und nennt 68 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Themen: Diabetes mellitus
Abstract (Originalsprache)
Diabetes mellitus, a prevalent global health challenge, significantly impacts societal and economic well-being. Islet transplantation is increasingly recognized as a viable treatment for type 1 diabetes that aims to restore endogenous insulin production and mitigate complications associated with exogenous insulin dependence. We review the role of mesenchymal stem cells (MSCs) in enhancing the efficacy of islet transplantation. MSCs, characterized by their immunomodulatory properties and differentiation potential, are increasingly seen as valuable in enhancing islet graft survival, reducing immune-mediated rejection, and supporting angiogenesis and tissue repair. The utilization of MSC-derived extracellular vesicles further exemplifies innovative approaches to improve transplantation outcomes. However, challenges such as MSC heterogeneity and the optimization of therapeutic applications persist. Advanced methodologies, including artificial intelligence (AI) and single-cell RNA sequencing (scRNA-seq), are highlighted as potential technologies for addressing these challenges, potentially steering MSC therapy toward more effective, personalized treatment modalities for diabetes. This review revealed that MSCs are important for advancing diabetes treatment strategies, particularly through islet transplantation. This highlights the importance of MSCs in the field of regenerative medicine, acknowledging both their potential and the challenges that must be navigated to fully realize their therapeutic promise.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Endocrinology, Institute of Translational Medicine, The First Affiliated Hospital of Shenzhen University, Shenzhen Second People's Hospital, Shenzhen, Guangdong, China.
- MetaLife Lab, Shenzhen Institute of Translational Medicine, Shenzhen, Guangdong, China.
- Biology Department, Skidmore College, Saratoga Springs, NY, United States.
- Imaging Department, The First Affiliated Hospital of Shenzhen University, Shenzhen Second People's Hospital, Shenzhen, Guangdong, China.
Zitieren
APA
Mou, L., Wang, T. B., Wang, X., & Pu, Z. (2024). Advancing diabetes treatment: the role of mesenchymal stem cells in islet transplantation. Frontiers in Immunology, 15. https://doi.org/10.3389/fimmu.2024.1389134
Vancouver
Mou L, Wang TB, Wang X, Pu Z. Advancing diabetes treatment: the role of mesenchymal stem cells in islet transplantation. Frontiers in Immunology. 2024;15. doi:10.3389/fimmu.2024.1389134
BibTeX
@article{Mou2024,
author = {Mou, Lisha and Wang, Tony Bowei and Wang, Xinyu and Pu, Zuhui},
title = {Advancing diabetes treatment: the role of mesenchymal stem cells in islet transplantation},
journal = {Frontiers in Immunology},
year = {2024},
volume = {15},
doi = {10.3389/fimmu.2024.1389134}
}
EUVIMED